Will cannabis equities finally break their range, or does the July calendar vacuum guarantee another week of drift?

Read the full US brief for 2026-07-19.

Will venue arbitrage or earnings silence define cannabis returns in the week ahead?

Read the full US brief for 2026-07-19.

CIN Newsroom — 2026-07-15

The daily audio brief for institutional cannabis investors. MSO earnings, distressed cannabis names, capital markets, and the numbers behind the news.

Method: Generated from the live CIN Newsroom tape at cin-newsroom.pplx.app. Freshness bucketing, mover selection, and issuer status are computed from the same tape that powers the CanIDeal terminal.

Cannabis Investor News is editorial. CanIDeal is the commodities terminal it reports from.

Trulieve's NYSE debut lifted ancillary suppliers and fertilizer plays by mid-single digits while multi-state operators drifted or sold off, exposing a liquidity gap that persists even after the first exchange uplist under the Trump administration's cancer-research carveout.

Read the full US brief for 2026-07-13.

Trulieve's NYSE debut has created a two-tier cannabis market, with ancillary suppliers jumping while multi-state operators fade, and no clear crossover catalyst emerging for broader plant-touching equities into Monday's open.

Read the full US brief for 2026-07-13.

CIN Newsroom — 2026-07-13

The daily audio brief for institutional cannabis investors. MSO earnings, distressed cannabis names, capital markets, and the numbers behind the news.

Method: Generated from the live CIN Newsroom tape at cin-newsroom.pplx.app. Freshness bucketing, mover selection, and issuer status are computed from the same tape that powers the CanIDeal terminal.

Cannabis Investor News is editorial. CanIDeal is the commodities terminal it reports from.

Will Trulieve's NYSE debut prove to be the sector inflection point or another false signal buried by rangebound drift?

Read the full US brief for 2026-07-12.

CytRx spiked three hundred twenty-nine percent on cannabinoid receptor trial data in a session that split cannabis equities cleanly down the middle: biotech plays with IP optionality found air while the core MSO cohort sat range-bound, waiting for regulatory clarity that still hasn't arrived.

Read the full US brief for 2026-07-10.

Cannabis equities open Thursday with breadth in expansion mode but no single catalyst large enough to drive conviction, as the sector waits for either SAFE Banking passage or final DEA guidance on Schedule III to break the range that has defined tape action for the past six weeks.

Read the full US brief for 2026-07-10.

Trulieve's NYSE debut on Tuesday split the cannabis tape in two — ancillary suppliers surged on crossover hope while multi-state operators drifted, exposing a liquidity gap that persists even after the first CSA-compliant uplist.

Read the full US brief for 2026-07-09.